850655-07-1

Basic information

• Product Name: 2'-O-(4''-O-tocopherylsuccinoyl)paclitaxel
• Synonyms: 2'-O-(4''-O-tocopherylsuccinoyl)paclitaxel
• CAS NO: 850655-07-1
• Molecular Weight: 1366.69
• Mol File: 850655-07-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2'-O-(4''-O-tocopherylsuccinoyl)paclitaxel(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-O-(4''-O-tocopherylsuccinoyl)paclitaxel(850655-07-1)
• EPA Substance Registry System: 2'-O-(4''-O-tocopherylsuccinoyl)paclitaxel(850655-07-1)

Safety Data

• Hazardous Substances Data: 850655-07-1(Hazardous Substances Data)

Upstream product

• 117527-50-1 2'-succinylpaclitaxel 
• 59-02-9 Tocopherol 
• 33069-62-4 taxol 
• 4345-03-3 vitamin E succinate 

Relevant articles and documents

CD44-Targeted Facile Enzymatic Activatable Chitosan Nanoparticles for Efficient Antitumor Therapy and Reversal of Multidrug Resistance

Nanoparticles are attractive platforms for the delivery of various anticancer therapeutics. Nevertheless, their applications are still limited by the relatively low drug loading capacity and the occurrence of multidrug resistance (MDR) against chemotherap

Antitumor agents. 258. Syntheses and evaluation of dietary antioxidant-taxoid conjugates as novel cytotoxic agents

Various dietary antioxidants, including vitamins, flavonoids, curcumin, and a coumarin, were conjugated with paclitaxel (1) through an ester linkage. The newly synthesized compounds were evaluated for cytotoxic activity against several human tumor cell lines as well as the corresponding normal cell lines. Interestingly, most tested conjugates selectively inhibited the growth of 1A9 (ovarian) and KB (nasopharyngeal) tumor cells without activity against other cell lines. Particularly, conjugates 16 and 20 were highly active against 1A9 (ED50 value of 0.005 μg/mL) as well as KB (ED50 values of 0.005 and 0.14 μg/mL, respectively) cells. Compound 22b, the glycinate ester salt of vitamin E conjugated with 1, appears to be a promising lead for further development as a clinical trial candidate as it exhibited strong inhibitory activity against Panc-1 (pancreatic cancer) with less effect on the related E6E7 (normal) cell line.